الفهرس 
Introduction
Ulcerative colitisOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
Background: Etiology and pathogenesis of UC are still not completely understood. However, it is likely that they result from complex interactions among the immune system, the environment and susceptibility genes. The extent of inflammation influences the patient’s management and the choice of delivery system for therapy. Topical treatments in the form of enemas or suppositories are usually the first line choice for proctitis and left-sided colitis, respectively Aim: The aim of the current study was to evaluate the possible anti-inflammatory and antioxidant effects of liraglutide; an approved incretin analog for the treatment of type 2 diabetes mellitus on experimentally induced dextran sulfate sodium (DSS) colitis in mice and comparing its effect with prednisolone as a standard treatment Setting: Medical experimental research center, Faculty of Medicine, Mansoura University. Results: Treatment of DSS induced colitis with prednisolone and liraglutide resulted in significant improvement on the level of colon length and histopathological results. Significant reduction in oxidative stress and inflammatory markers NO, MDA and VCAM-1 was achieved using this dose of liraglutide. While significant increase in GSH level was achieved. These results show that the antidiabetic drug liraglutide can exert anti-inflammatory and antioxidant actions Conclusion: liraglutide may represent a novel potential approach for the pharmacotherapy of UC by triggering antioxidant and anti-inflammatory mechanisms with possibly, fewer adverse effects than shown by steroid therapy. So, liraglutide is potentially useful in UC treatment especially in diabetic patient or patient having contraindication to corticosteroids.